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Can risk modelling improve treatment
decisions in asymptomatic carotid stenosis?
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Abstract
Background: Carotid endarterectomy (CEA) is routinely performed for asymptomatic carotid stenosis, yet its
average net benefit is small. Risk stratification may identify high risk patients that would clearly benefit from
treatment.
Methods: Retrospective cohort study using data from the Asymptomatic Carotid Atherosclerosis Study (ACAS). Risk
factors for poor outcomes were included in backward and forward selection procedures to develop baseline risk
models estimating the risk of non-perioperative ipsilateral stroke/TIA. Baseline risk was estimated for all ACAS
participants and externally validated using data from the Atherosclerosis Risk in Communities (ARIC) study. Baseline
risk was then included in a treatment risk model that explored the interaction of baseline risk and treatment status
(CEA vs. medical management) on the patient-centered outcome of any stroke or death, including peri-operative
events.
Results: Three baseline risk factors (BMI, creatinine and degree of contralateral stenosis) were selected into our baseline
risk model (c-statistic 0.59 [95% CI 0.54–0.65]). The model stratified absolute risk between the lowest and highest risk
quintiles (5.1% vs. 12.5%). External validation in ARIC found similar predictiveness (c-statistic 0.58 [0.49–0.67]), but poor
calibration across the risk spectrum. In the treatment risk model, CEA was superior to medical management across the
spectrum of baseline risk and the magnitude of the treatment effect varied widely between the lowest and highest
absolute risk quintiles (3.2% vs. 10.7%).
Conclusion: Even modestly predictive risk stratification tools have the potential to meaningfully influence clinical decision
making in asymptomatic carotid disease. However, our ACAS model requires target population recalibration prior to
clinical application.
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Background
Asymptomatic carotid endarterectomy (CEA) is com-
monly performed, yet, considerable uncertainty exists
about the magnitude of benefit and which patients
should be treated [1]. The best estimates of the risk-
benefit ratio of CEA are derived from trials performed in
the 1990s [2, 3]. These trials found a consistent, but
small, average absolute reduction in stroke risk, approxi-
mately 1 in 100 people per year.
For a variety of conditions and treatments, the risks
and benefits of treatment can vary markedly between
higher and lower risk patients [4, 5]. For example, in
symptomatic carotid stenosis, patients with the highest
stroke risk have more than a 50% risk of stroke over 2
years whereas those with the lowest risk have less than a
10% risk [6]. Assuming, as seems to be the case, that
CEA has similar relative benefits across risk groups, the
highest risk patients would have more than 30 in 100
risk reduction over 2 years (1 stroke prevented after 2
years per no more than 3 CEAs [NNT < 3]) vs. a much
smaller net benefit in the lowest risk patients (NNT >
15) [7]. Given the relatively high stroke risk of symptom-
atic patients, however, even relatively lower risk patients
may receive a meaningful net benefit from CEA, but this
may not be true for lower risk asymptomatic patients. If,
as with symptomatic carotid stenosis, higher risk pa-
tients have a larger benefit from treatment than lower
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risk patients, then a paradigm of CEA for higher-risk
asymptomatic patients and medical management for
lower-risk patients could address much of the asymp-
tomatic carotid treatment controversy. For this reason,
tools to stratify asymptomatic carotid risk have been
established as a high research priority [8].
To inform tools to stratify asymptomatic CEA risk, we
sought to determine how baseline risk of important out-
comes varies in the Asymptomatic Carotid Atheroscler-
osis Study (ACAS).
Hypothesis
We hypothesized that: 1. clinically meaningful variation
in risk would exist in ACAS and readily be predicted by
baseline clinical factors and 2. No variation in relative
treatment benefit would exist across the risk spectrum,




ACAS was a clinical trial that randomized patients to
CEA or medical management in a 1:1 ratio in the con-
text of 60% or greater asymptomatic carotid stenosis [2].
ACAS data is available, after application, from the Na-
tional Institute of Neurological Disorders and Stroke
(NINDS) archived clinical research datasets repository
[9]. We used ACAS data to explore how clinical factors,
measured at study entry, predict outcomes in medically
and surgically treated patients by first incorporating
these factors into a baseline risk model. After stratifying
patients by baseline risk, we then explored how patient-
centered outcomes varied across baseline risk using a
treatment outcomes model.
A limitation of using ACAS to study carotid risk strati-
fication is that both medical and surgical management
have evolved considerably over the 20 years since
ACAS’s publication. Yet, ACAS is a reasonable dataset
to explore our primary hypotheses for two reasons. First,
without randomization, it is impossible to determine
whether medical and surgical treatment work differently
in high and low risk patients. While observational stud-
ies provide insights into risk factors, non-random treat-
ment assignment limits any inferences about the
relationship between risk and treatment status. Second,
while it is likely that absolute stroke and death rates
have decreased since ACAS, for both medically and sur-
gically treated patients, it is less likely that the relative
relationship between risk factors and event rates has
evolved. For example, because the absolute mortality
rates in statin trials range from 0 to 20% based on the
trial timing and population, there is wide variation in the
absolute risk reductions from 0% per year to over 2%
per year even though the relative effect sizes of statins
are fairly consistent across studies [10]. If similar logic
applies to CEA then, then while the absolute event rates
in ACAS would likely overestimate the event rates in
modern care, a patient that was “high risk” in ACAS
would still be “high risk” today, even though the absolute
level of risk would likely be lower today.
To test our first hypothesis, that risk for adverse out-
comes would vary over the ACAS population, we built a
baseline risk model to determine how effectively multi-
variable risk factor models would predict the risk of ipsi-
lateral stroke/TIA. To test our second hypothesis and
explore how patient-centered outcomes vary across the
spectrum of baseline risk, we build a treatment outcome
model that determined how treatment influences out-
comes after accounting for baseline risk.
Baseline risk model
Conceptually, the goal of this model was to estimate which
factors measured at the time of randomization, influence
longer term stroke risk to distinguish “low risk” from “high
risk” patients independently of their treatment assignment.
Baseline risk models were derived on the whole study
population, including both treatment arms as this approach
is suggested to improve statistical power without introdu-
cing bias [11]. The primary outcome for the baseline risk
model was selected to best stratify which patients with ca-
rotid stenosis were at highest risk from stroke related to
that carotid. Thus, our primary outcome was non-
perioperative ipsilateral stroke or ipsilateral transient ische-
mic attack. The decision to combine stroke and TIA was
made because some events classified as TIAs in ACAS
would likely be classified as strokes today —temporally pro-
longed TIAs typically have evidence of infarction on MRI
imaging and such lesions are now classified as strokes while
ACAS was largely conducted in the pre-MRI era [12]. Peri-
operative events were excluded from the primary model so
that the baseline risk construct would not reflect treatment
assignment. Instead, these events are accounted for in the
treatment risk model. Death was omitted from the baseline
risk model because it was a relatively uncommon outcome
and when it occurs is most commonly unrelated to carotid
disease. Given that many different notions of “baseline” and
to account for changes in event definitions over time risk
may be relevant in asymptomatic carotid disease, we also
explored alternate baseline risk models for outcomes in-
cluding: 1. Non-perioperative ipsilateral stroke 2. Any non
peri-operative stroke or TIA 3. Any non peri-operative
stroke, excluding TIAs.
Factors for consideration in the baseline risk models
were identified via a manual literature search to identify
factors associated with stroke after CEA. This search
identified 15 factors: age [2, 13], sex [14], degree of ca-
rotid ipsilateral stenosis, [3, 13] hypertension, [15]
hyperlipidemia, [15] diabetes, [16] history of stroke/TIA,
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[16] coronary artery disease, [6] peripheral vascular dis-
ease, [6] chronic renal insufficiency, [17] congestive
heart failure [18], bilateral carotid disease, [3] contralat-
eral carotid occlusion [6], smoking [15]. and body mass
index [19]. These factors were then mapped to the
ACAS dataset. Other factors that putatively predict
stroke risk were omitted because they could not be
mapped to ACAS, for example, progression of carotid
stenosis [20]. In most cases, this mapping was straight-
forward (e.g. age), however, in some instances the
process required modest additional assumptions. This
was most notable for degree of carotid stenosis. In
ACAS, patients could be enrolled by varying stenosis cri-
teria, with most qualifying based on Doppler ultrason-
graphy and a smaller subset receiving conventional
angiography. Patients were assigned to stenosis categor-
ies (0–60%, 60–80, 80–100%) for each carotid artery
preferentially using the conventional angiography degree
(more similar to the NASCET approach than the ECST
approach) of stenosis and then the doppler if no angio-
gram was performed.
For each outcome, backwards selection was used to
identify factors for inclusion in the final baseline risk
model. Given the number of outcomes in the primary
baseline risk model (n = 122) we were only modestly at
risk for over-fitting by including 14 predictor variables
in the model prior to selection [21]. Factors were
retained in the final model if the p-value for a given fac-
tor was less than 0.15. To assess and account for over-
fitting that can be induced by the variable selection
process, models were internally validated by repeating
the model with 10,000 bootstrap samples and shrinkage
factors were calculated [22–24]. To ensure that the fac-
tors selected into the primary model was stable, forward
selection models were built by serially including the fac-
tors with the strongest univariate associations with each
outcome and retained in the final forward-selection
model if the addition of those factors reduced the Akai-
kie Information Criterion (AIC). All models were Cox
models and individuals were censored if they died or
had a perioperative stroke in model that did not include
these elements as part of its outcome definition. Baseline
risk was assessed for each patient by estimating the cu-
mulative hazard at median study follow-up duration for
each individual.
Treatment outcomes model
In a second step, we incorporated the baseline risk in-
formation into a second model to determine treatment
effectiveness on patient-centered outcomes across the
spectrum of baseline risk. First, we explored whether
relative heterogeneity of treatment effect may exist for
any factor included in the baseline risk model by deter-
mining whether there was an interaction with each
factor included in the final risk model and a treatment
indicator variable (medical vs. surgical). When no sig-
nificant interactions were identified, we built a treat-
ment outcomes model with a primary outcome of any
stroke, TIA or death, including peri-operative events.
This outcome was selected because it was considered to
be of the overall greatest clinical relevance to patients
and consequently if these models were to be used for
clinical decision-making, this is the model that would
be most relevant to patients. Then we built a Cox
model to predict any stroke, TIA or death with
dependent variables including baseline risk (determined
from the baseline risk model), a treatment indicator
and the interaction between baseline risk and treat-
ment. Model discrimination was calculated with Har-
rell’s c-statistic. Calibration plots were derived for both
models by comparing actual and predicted risk, at mean
trial follow-up (3.8 years) across quintiles of predicted
risk. Average marginal effects were used to estimate
risks for treated and untreated patients across the
spectrum of baseline risk.
External validation of baseline risk model
We used data from the Atherosclerosis Risk in Com-
munities (ARIC) cohort component to determine how
well the baseline risk model predicted risk in a real
world population. The goal of this external validation
was to determine wheher our trial-derived ACAS model
would have sufficient correlation with real-world risk to
allow such a model to be applied in real world practice.
In brief, ARIC followed a cohort of individuals aged
45–64 at initial examination in four communities with
comprehensive clinical examinations including 4-waves
of carotid ultrasound examination between 1987 and
1999, roughly paralleling when ACAS was performed
[25]. We identified patients with > 60% carotid stenosis
using B-mode ultrasound and applying a previously val-
idated technique [26]. Stroke was identified in ARIC by
annually contacting patients, collecting information on
hospitalizations and ultimately by nurse abstraction of
hospitalization records as previously described. Based
on these data, stroke events were classified based on
the underlying data as definite/probable embolic or
thrombotic ischemic stroke [27]. We then estimated
baseline risk in the ARIC population using all baseline
risk models derived in ACAS and estimated model dis-
crimination using Harrell’s c-statistic. Calibration was
assessed by comparing the predicted risk of stroke
(using the secondary baseline risk model with all
strokes/no TIAs as its outcome, as this model most
closely mapped to the stroke outcome measured in
ARIC) with baseline survival from mean trial follow-up
in ACAS vs. actual event rates in ARIC.
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Research ethics
The University of Michigan Institutional Review Board
reviewed the study protocol and declared it exempt as it
relied on de-identified data.
Results
Summary of baseline risk models
In the primary baseline risk model, the same 3 factors were
retained in the forward and reverse selection models: cre-
atinine, body mass index, and degree of contralateral sten-
osis. All other factors had multivariable p-values > 0.15 and
failed to reduce the AIC when added to this baseline model.
When secondary outcomes were considered, contralateral
stenosis was the only factor that consistently retained across
models with a trend towards increased risk for 60–80% sten-
osis and decreased risk with 80–100% stenosis. For models
including all strokes, as opposed to only ipsilateral strokes,
other conventional vascular risk factors, such as age, blood
pressure, smoking and diabetes, were included (Table 1).
Performance of baseline risk model
The overall predictiveness of the baseline model was
modest with a C-statistic of 0.59 [95% CI 0.54–0.65].
This model also had some evidence of over-fitting as
the shrinkage coefficient was 0.85. Individual-level
estimated risks at the mean time to last follow-up,
from the model, are illustrated in Fig. 1. The lowest
risk patients had a model-estimated risk over the
course of the trial just under 3% and the highest risk
patients estimated risks around 35%. The proportion
of the lowest risk quintile with non-perioperative ip-
silateral stroke/TIA was 5.1% vs. 12.5% in the high-
est risk quintile. The primary baseline risk model
was well-calibrated compared to actual risk in the
lowest two quintile of risk, over-predicted risk in the
3rd quintile and under-predicted in the two highest
risk quintiles (Fig. 2).
In external validation, the primary baseline risk
model had similar predictiveness in ARIC as in
ACAS (C-statistic 0.58 vs. 0.58). Models predicting
other outcomes had variable performance. The ipsi-
lateral stroke model performed slightly worse in
ARIC (0.63 vs. 0.57), the all stroke/TIA model very
poorly (0.60 vs. 0.48) and the all stroke model per-
formed about the same (0.61 vs. 0.60) in the in-
ternal and external models. However, calibration was
poor. In ARIC, 16.4% of the population had a stroke
at a mean follow-up of almost 11 years compared to
Table 1 Summary of Baseline Risk Models. Regression coefficients for continuous variables represent the hazard for a one unit





Secondary Outcome — All
Stroke/TIA
Secondary Outcome - All
Stroke




1.43 0.13 1.57 0.18 1.37 0.07 1.49 0.09
Contralateral Stenosis 80-100%
(ref 0-60%)
0.65 0.12 0.84 0.42 0.81 0.26 0.77 0.34
Creatinine 1.46 0.01 1.31 0.05
BMI 1.05 0.02 1.05 0.05
Abnormal Heart Rhythm 0.4 0.12
Any prior vascular disease
(CVD, PVD)
0.59 0.1 1.28 0.08
Diabetes 1.3 0.1
Age 1.01 0.27 1.02 0.19
Smoking 1.6 0.002 1.92 0.001
Mean Diastolic BP 1.01 0.05 1.02 0.04
Model Parameters
N 1551 1575 1622 1648
Number Outcomes 115 56 215 113
c-statistic 0.59 [0.54-0.65] 0.63 [0.57-0.71] 0.60 [0.56-0.64] 0.62 [0.56-0.67]




0.58 [0.49-0.67] 0.57 [0.47-0.68] 0.49 [0.40-0.59] 0.58 [0.48-0.68]
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6.7% at 3.8 years in ACAS (9.2% in the medical arm
and 4.5% in the surgical arm). When accounting for
the differential length of follow-up by extrapolating
the ACAS baseline survival function into the ARIC
population, the ACAS model substantially overesti-
mated risk, across the risk spectrum, but particularly
in the highest risk patients — 9.1% estimated risk
vs. 4.5% actual risk in the lowest risk quintile to
24.6% vs. 10.5% in the highest risk quintile Fig. 3.
Treatment outcome model
The treatment outcome model was only modestly predictive,
C-statistic: 0.56 [0.52–0.60] Predicted risk was reasonably
well calibrated to actual risk across the risk spectrum for
both CEA and medical management (Fig. 4) The predicted
risk of any stroke, TIA or death was lower across the baseline
risk spectrum with CEA compared to medical management.
The interaction term in the model was non-significant (p=
0.17), but the direction of the interaction resulted in greater
Fig. 1 Histogram displaying basleine risk distribution of the primary baseline risk model — Estimated Risk of Ipsilateral Stroke/TIA — in the
ACAS population
Fig. 2 Calibration of the baseline risk model in the ACAS population across quintiles of baseline risk
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expected relative treatment benefit amongst the pateitns at
highest baseline risk. The absolute treatment effect increased
across the risk spectrum (Fig. 5) such that the absolute risk
reduction in stroke/TIA or death in the lowest risk quintile
was 3.2% with CEA vs. 10.7% in the highest risk quintile.
Discussion
Our risk model using 3 simple clinical factors demon-
strates the potential of risk stratification to improve
asymptomatic carotid treatment decisions. When applied
to the ACAS trial, this model was able to demonstrate
Fig. 3 Calibration of the baseline risk model (derived in the ACAS population) in the ARIC population
Fig. 4 Calibration of the treatment outcome model in the ACAS population
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that the magnitude of treatment benefit varies 3-fold be-
tween the quintile with the greatest and least benefit of
CEA. While the ACAS trial was performed some time
ago, given the absence of more recent controlled trials in
asymptomatic stenosis, they are the best available data
to study this question. However, while this model is
promising and provides proof of principle, it should not
yet be applied to clinical care. Calibration needs to be
improved. Our ACAS model overestimated risk in a
real-world external validation dataset, ARIC, and the
magnitude of overestimation increased in the highest
risk subpopulation.
Applying risk prediction models at the bedside re-
quires that models are both sufficiently discriminant and
are adequately calibrated. While our baseline risk model
reliably identified which patients were at the highest risk
(comparable predictiveness), it substantially overesti-
mated the actual level of risk in ARIC (poor calibration).
Evaluation of clinical risk models often focuses on pre-
dictiveness — how well the model determines which pa-
tients are high vs. low risk, often measured with a
summary statistic such as the C-statistic. While our
model’s discrimination is only moderate, it echoes prior
literature that argues that even a moderately predictive
model can be clinically actionable [28]. Patients in our
model’s top risk quintile have risk more than double the
median risk — a group that, if ACAS event rates repre-
sented real world event rates, would almost certainly
benefit from CEA for asymptomatic disease and likely
represents a substantial number of real world patients.
However, to apply our model in the real world it must
also be adequately calibrated. That is not the case for
our model — which provides a striking example of the
limitations of poorly calibrated risk models. The average
patient in ACAS has about a 7% baseline risk of stroke
which translates into an approximately 5% absolute risk
reduction in stroke or death over a median of 3.7 years
of follow-up with CEA over medical management. If,
however, an apparently similar patient outside the trial
had a true baseline risk that was half as high as sug-
gested by our ARIC external validation (i.e. 3.5%), that
would translate into an absolute risk reduction around
1% over a similar time frame. Given that many have ar-
gued that asymptomatic CEA is ill-advised even if the
ACAS effect size was realistic, a 5-fold smaller effect
would substantially alter the treatment calculus. The
problem with clinically applying a poorly calibrated
model is that its difficult to know which calibration
standard to apply to a given population. If the ARIC
standard is more realistic, then asymptomatic CEA
should likely be used sparingly, if at all. If the ACAS
standard is more realistic, then asymptomatic CEA likely
represents a reasonably effective treatment option for a
substantial fraction of patients with asymptomatic ca-
rotid stenosis.
Both medical [29] and surgical [30] treatment have im-
proved considerably since ACAS, and ongoing trials will
clarify several key parameters relevant to decisions re-
garding asymptomatic CEA (i.e. expected event rates ac-
counting for improvements in best medical and surgical
treatments.) [31] Yet, if outcome-driving factors influ-
ence trial seletion, as may be the case with ACAS and
Fig. 5 Predicted risk with and without treatment, across the spectrum of basline risk, in ACAS
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ARIC, ongoing trials may not inform the anticipated
value of treatment in the unselected population. Asses-
sing external validity is a challenge for all trials. But, it is
uniquely challenging for asymptomatic carotid disease
because patients are not selected via population-based
screening (as in ARIC), but variably in the context of ei-
ther non-vascular symptom presentations (e.g. syncope)
or via screening in the context of comorbid vascular dis-
ease. Clinical registries may mitigate some such selection
biases by reflecting treatment decisions in the real world
as opposed to the trial enviornment, however, they still
can not account for the possibility that real world pa-
tients are likely much higher risk that patients that
would have been identified by population-based screen-
ing. Even if modern trials provide clear and convincing
evidence of the benefits of treatment in modern asymp-
tomatic populations, the question of which population
the results apply to will remain a challenge.
The problem of adequately discriminant, but poorly cali-
brated, risk models is common. For example, the widely
used atherosclerotic cardiovascular disease (ASCVD) risk
score has varying calibration depending on the study popu-
lation [32]. Yet, poor calibration does not necessarily pre-
clude application of such models. Instead, it may simply
require that the model be recalibrated to the target popula-
tion. In the case of ASCVD, prior work has shown that sim-
ple recalibration techniques (e.g. estimating new model
intercepts or re-estimating model coefficients) represent a
plausible strategy to maintain the conceptual framework of
the underlying model while generating well-calibrated pre-
dictions. For example, Sussman et al. have found that while
the ASCVD risk models substantially over-estimated risk
(resulting in unduly aggressive treatment recommenda-
tions) in a Veteran Affairs population, but that simple recal-
ibration that maintained the conceptual framework of
ASCVD (and even the model coefficients) resulted in vastly
improved calibration and more accurate treatment deci-
sions [33]. Applying a similar approach to our carotid
models is generally feasible in an era of Big Data and has
the potential to substantially inform carotid decision-
making by applying 3 steps 1. For a given target population
(e.g. clinic, health system, hospital), extract real world data
on outcomes in patients with asymptomatic carotid sten-
osis, likely using electronic medical record data. 2. Fit a
model by including the predictor variables in our model in-
dependently (completely refitting a model in the target
population) or by calculating the linear predictor of our
model (fitting a new intercept in the target population) and
do the same for perioperative risk using previously devel-
oped models. 3. Verify model predictiveness and calibration
in the target population. While the poor calibration of our
model precludes direct clinical application there is consid-
erable potential to apply this technique to improve carotid
decisions after appropriate recalibration.
Understanding the poor calibration of our model may
inform carotid decision-making. A number of factors
may contribute to the poor calibration of the ACAS
model in ARIC. First, measurable patient characteristics
differ between samples —the mean age in ACAS (67) is
considerably greater than the mean in our ARIC sample
(62). However, age does not strongly predict stroke risk
in either sample. A more likely explanation is that ACAS
patients were at higher baseline risk due to clinical fac-
tors that led to them undergoing carotid screening in
the first place. In ARIC, carotid stenosis was detected by
screening comprehensively a large population regardless
of baseline risk. In ACAS, conversely, patients received
carotid testing based on real-world clinician practice,
probably due to patients having some underlying clinical
condition, thereby selecting fo a population at consider-
ably higher risk of stroke. Another possibility is that risk
factor management differed between studies, but this
seems relatively unlikely given that both studies were
conducted in similar epochs, and, if anything, we would
have anticipated that trial participants would have more
intense risk factor management than patients in the
community. Yet another possibility, is that the stroke-
definition or definition of carotid stenosis was more sen-
sitive in ACAS than in ARIC. More broadly, the differ-
ences in stroke risk between screening-identified cohort
and a clinically-identified cohort illustrates one of the
key challenges in treating patients with asymptomatic
stenosis. It is likely that the rationale for detection influ-
ences stroke risk, but the mechanisms underlying that
increased risk are not well known.
While poor calibration is the primary barrier to the
clinical application of these models, predictiveness is also
only modest and is considerably worse than in prior
work [34]. This likely reflects several factors. First, the
clinical factors surrounding the symptomatic event (e.g.
amaurosis vs. TIA vs. stroke and time from event) are
key predictors in the symptomatic context, but are not
relevant to to asymptomatic patients. Second, plaque
charateristics (e.g. ulcerated plaque) were also important
predictors in the symptomatic models, but were not
available in most ACAS patients because they qualified
for the trial on the basis of ultrasound evaluations that
are insensitive to these features compared to the more
sensitive angiograms that were applied in the symptom-
atic trials. It is plausible that other plaque factors are
also important predictors (e.g. plaque length, location,
deree of calicifcation) but can not be included in this
model because they were not systematically measured in
the non-surgical arm in ACAS. Finally, ipsilateral degree
of stenosis is a strong predictor in the symptomatic con-
text, but not the asymptomatic context. The reasons
why this is the case are unclear and numerous possible
explanations exist (e.g. measurement error and limited
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statistical power). It is also possible that the “true” story
about the relationship between degree of stenosis is
complex. For example, plaque characteristics and degree
of stenosis may interact to increase risk. Amongst symp-
tomatic patients, then, the fact that they have had an
event results in selection of group with a combination of
high risk plaque features such that ipsilateral stenosis is
an important predictor whereas amongst asymptomatic
patients have, on the whole, lower risk plaque character-
istics such that ipsilateral stenosis is a weak predictor.
An additional limitation of our models is that the factors
selected for the models were not the factors with our
strongest prior probabilities (e.g. contralateral stenosis
selected into the model instead of ipsilateral stenosis).
Similarly, the coefficients associated with these factors
does not fit strongly with our priors (i.e. higher risk with
60–80% contralateral stenosis vs. 80–100% contralateral
stenosis). These findings suggest that the credibility of
our models should be judged carefully and that they may
reflect some combination of random error, overfitting,
omitted variable bias or confounding.
Conclusions
Our risk model using 3 simple clinical factors demon-
strates the potential of risk stratification to improve
asymptomatic carotid treatment decisions. However,
poor calibration on external validation limits its immedi-
ate and direct clinical applicability.
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